Wolfgang Schutte
Overview
Explore the profile of Wolfgang Schutte including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
28
Citations
336
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Reinmuth N, Gessner C, Schichtl T, Schutte W, Hammerschmidt S, Schulz H, et al.
Cancer Treat Res Commun
. 2025 Mar;
43:100878.
PMID: 40023002
Background: Atezolizumab is the first approved PD-L1 inhibitor for patients with advanced non-small cell lung cancer (NSCLC) in Germany. This study aimed to assess effectiveness and safety of this checkpoint...
2.
Schreiber J, Schutte W, Koerber W, Seese B, Koschel D, Neuland K, et al.
Pneumologie
. 2024 Apr;
78(4):236-243.
PMID: 38608658
Introduction: Pirfenidone was the first anti-fibrotic drug approved in Europe in 2011 for the treatment of mild-to-moderate idiopathic pulmonary fibrosis. Objectives: To investigate the clinical course of mild-to-moderate idiopathic pulmonary...
3.
Dorr N, Kruger M, Moller M, Zinne N, Toennies M, Schega O, et al.
Eur J Cardiothorac Surg
. 2024 Mar;
65(4).
PMID: 38479834
Objectives: Solitary fibrous tumours of the pleura (SFTP) are historically considered to be benign soft tissue neoplasms. However, a clinical relevant number of these neoplasms have malignant histological features. The...
4.
Utzig M, Hoffmann H, Reinmuth N, Schutte W, Langer T, Lobitz J, et al.
Pneumologie
. 2023 Dec;
78(4):250-261.
PMID: 38081218
Background: In 2022, an update of the German lung cancer guideline, first published in 2010 and revised in 2018, was released. This article aims to show the process of updating,...
5.
Moller M, Kruger M, Schutte W
Dtsch Med Wochenschr
. 2023 Nov;
148(22):1462-1466.
PMID: 37918432
Lung carcinoma is still one of the most common forms of cancer in both sexes in Germany and the most common cause of cancer-related death. However, we are in the...
6.
Schutte W, Gutz S, Nehls W, Blum T, Bruckl W, Buttmann-Schweiger N, et al.
Pneumologie
. 2023 Oct;
77(10):671-813.
PMID: 37884003
The current S3 Lung Cancer Guidelines are edited with fundamental changes to the previous edition based on the dynamic influx of information to this field:The recommendations include de novo a...
7.
Moller M, Schutte W, Turzer S, Seliger B, Riemann D
Cancers (Basel)
. 2023 Oct;
15(19).
PMID: 37835567
An important challenge remains in identifying the baseline characteristics of cancer patients who will mostly benefit from immune checkpoint inhibitor (ICI) therapies. Furthermore, biomarkers could help in the choice of...
8.
Milger K, Korn S, Feder C, Fuge J, Muhle A, Schutte W, et al.
Pneumologie
. 2023 Aug;
PMID: 37625439
Background: The introduction of monoclonal antibodies (biologics) has revolutionized the therapy of severe asthma. Even though there is a response in the majority of patients, the degree of response varies....
9.
Riemann D, Turzer S, Ganchev G, Schutte W, Seliger B, Moller M
Biomolecules
. 2023 Feb;
13(2).
PMID: 36830562
In this exploratory prospective observational study on 40 small cell lung cancer (SCLC) patients treated with a combination of chemotherapy and immune checkpoint inhibitors, blood immune cells were characterized by...
10.
Milger K, Korn S, Feder C, Fuge J, Muhle A, Schutte W, et al.
Pneumologie
. 2023 Feb;
77(4):220-232.
PMID: 36796422
Background: The introduction of monoclonal antibodies (biologics) has revolutionized the therapy of severe asthma. Even though there is a response in the majority of patients, the degree of response varies....